Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial.

Bancha SatirapojKhanin WatanakijthavonkulOuppatham Supasyndh

Published in: PloS one (2018)

Pioglitazone 7.5 mg once daily treatments presented similar glycemic control to standard dose pioglitazone and exhibited beneficial effects on weight gain and fluid retention among patients with type 2 diabetes and CKD.

Keyphrases

glycemic control
type diabetes
weight gain
chronic kidney disease
low dose
body mass index
weight loss
blood glucose
end stage renal disease
birth weight
insulin resistance
cardiovascular disease
physical activity
high dose
metabolic syndrome
adipose tissue
gestational age
preterm birth